Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
July 2013, Vol 4, No 6
July 2013, Vol 4, No 6
How Employers Are Adapting to the New Landscape in Healthcare
By
Caroline Helwick
July 2013, Vol 4, No 6
With the new landscape of healthcare delivery yet to come into sharp focus, employers are living in “the land of confusion,” wondering how they will conform to new requirements, meet the expectations of their employees, and remain profitable, said Peter Hayes, Principal, Healthcare Solutions, Duluth, GA, at the Third Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Two Genetic Tests Can Prevent Overtreatment of Early Prostate Cancer
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
July 2013, Vol 4, No 6
The management of patients with prostate cancer will be advanced by 2 new genetic tests—Oncotype DX prostate cancer test and Prolaris.
Read Article
Nearly 1 in 5 Patients with Cancer Reports Financial Distress
By
Audrey Andrews
Economics & Value
,
Economics of Cancer Care
July 2013, Vol 4, No 6
Financial distress is prevalent among insured patients with cancer, and although most patients state a desire to talk to their physicians about costs, this discussion rarely occurs, according to a study conducted at Duke University Medical Center, Durham, NC.
Read Article
Cancer Rehabilitation: The Next Frontier in the Care Continuum
By
Caroline Helwick
Cancer Rehabilitation
July 2013, Vol 4, No 6
Cancer rehabilitation is “the next frontier” in survivorship care, according to Julie K. Silver, MD, Assistant Professor of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, MA.
Read Article
Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases
By
Lisa A. Raedler, PhD, RPh
Drug Updates
July 2013, Vol 4, No 6
Prostate cancer is the second leading cause of cancer-related death in the United States among men and the most frequently diagnosed cancer in American males. Among patients with metastatic prostate cancer, up to approximately 90% have bone metastases.
Read Article
The Leucovorin Shortage: A Tangled Web of Similar Isomers and Huge Cost Differences
By
Laura R. Bobolts, PharmD, BCOP
;
Valerie Fishman, RN
;
Marc Fishman, MD
;
William Hrushesky, MD
;
Dinah Huff, MD
;
Jurgen Kogler, MD
;
William Shimp, MD
Drug Updates
July 2013, Vol 4, No 6
After being in short supply since 2008, leucovorin, an analog of folic acid, is now more readily available, and the economics of US cancer care are about to have a bit of a reprieve.
Read Article
Prostatic Inflammation Protects Against Prostate Cancer
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
July 2013, Vol 4, No 6
Niagara Falls, Ontario—New data presented at the 2013 Canadian Urological Association annual meeting suggest that prostatic inflammation can reduce the risk for developing prostate cancer.
Read Article
Comparing the Impact of ADT Agents on Cardiovascular Events and Death in Men with Prostate Cancer
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
July 2013, Vol 4, No 6
Niagara Falls, Ontario—Among men with prostate cancer and preexisting cardiovascular (CV) disease, the risk of CV events or CV-related death is cut in half when they receive androgen-deprivation therapy (ADT) with degarelix (Firmagon) instead of the luetinizing hormone–releasing hormone (LHRH) agonists goserelin (Zoladex) or leuprolide (Lupron), according to results of a new analysis presented at the 2013 Canadian Urological Association annual meeting.
Read Article
Genomic Sequencing Uncovers the Genetic Landscape of Primary CNS Lymphoma
By
Dalia Buffery, MA, ABD
Personalized Medicine
July 2013, Vol 4, No 6
Lugano, Switzerland—The genomic basis of primary central nervous system lymphoma (PCNSL), a very aggressive and incurable type of lymphoma, has not been understood until now. At the 2013 International Conference on Malignant Lymphoma, a team of researchers from the Mayo Clinic and from the University of Virginia presented its recent findings at a poster session involving the most comprehensive study to date of the genomic landscape of PCNSL.
Read Article
Implications for Oncology after Supreme Court Ruling that Genes Cannot Be Patented
By
Rosemary Frei, MSc
Health Policy
,
Policies & Guidelines
July 2013, Vol 4, No 6
The US Supreme Court’s ruling on June 13 in the case of the
Association for Molecular Pathology v Myriad Genetics
will have significant implications for the future of cancer testing, molecular diagnostics, and treatment.
Read Article
Page 3 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma